Image 4 1 1

LONDON, U.K. AND NEW YORK, U.S. (22 September 2022). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, resilience-based, connected health solution for chronic condition management, announces that it will release its unaudited interim results for the six months ended 30 June 2022 on 30 September 2022. Investor Presentation In addition to arranging customary meetings with institutional investors, Dr. Marla Dubinsky, Chief Executive Officer, and Stephen Young, Chief Financial Officer, will also provide a live presentation relating to the interim results via the Investor Meet Company platform on 3 October 2022 at 15:30 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Trellus Health via: Investors who already follow Trellus Health on the Investor Meet Company platform will automatically be invited. Download full announcement For further information please contact: Trellus Health plc Julian Baines, Chairman Via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker) Aubrey Powell / Jen Boorer Tel: 020 7496 3000

Walbrook PR Limited Paul McManus / Sam Allen Tel: 020 7933 8780 or [email protected] Mob: 07980 541 893 / 07502 558 258

About Trellus Health plc ( Trellus Health (LSE: TRLS) is the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden and promoting individual health behaviors that enable thriving in the face of a chronic condition. Through its TrellusElevate™ connected care platform and companion App, the company addresses both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system. The Company is initially focused on Inflammatory bowel disease (“IBD”), which includes the chronic incurable conditions of Crohn’s Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions, including Irritable Bowel Syndrome (“IBS”). The TrellusElevate™ platform is the Company’s proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. IBD patients treated using the methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following program completion (source: ). The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health’s patent-pending GRITT™ resilience assessment and personalized treatment methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost. Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS.

Published September 22, 2022